{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:35:59Z","timestamp":1790861759391,"version":"4.1.0"},"reference-count":13,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2005,8,2]],"date-time":"2005-08-02T00:00:00Z","timestamp":1122940800000},"content-version":"vor","delay-in-days":1796,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2000,9]]},"abstract":"<jats:p><jats:bold>Summary: <\/jats:bold>  <jats:italic>Purpose<\/jats:italic>: To evaluate the efficacy and tolerability of levetiracetam (LEV, Keppra) as add\u2010on therapy in patients with refractory partial seizures.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>: In this European multicenter, double\u2010blind, randomized, placebo\u2010controlled trial, LEV (500 or 1,000 mg twice daily) was compared with placebo as add\u2010on therapy in 324 patients with uncontrolled simple or complex partial seizures, or both, with or without secondary generalization. After enrollment, three parallel groups were assessed during a baseline period of 8 or 12 weeks, followed by a 4\u2010week titration interval and a 12\u2010week evaluation period.<\/jats:p><jats:p> <jats:italic>Results<\/jats:italic>: LEV significantly decreased partial seizure frequency compared with placebo. A reduction in seizure frequency of 50% occurred in 22.8% of patients in the 1,000\u2010mg group and 31.6% of patients in the 2,000\u2010mg group, compared with 10.4% of patients in the placebo group. Administration of LEV did not affect plasma concentrations of concomitant an\u2010tiepileptic drugs or alter vital signs or laboratory parameters. No significant difference in the incidence of adverse events was observed between treatment groups (70.8% for the 1,000\u2010mg group and 75.5% for the 2,000\u2010mg group), or between the LEV and placebo groups (73.2% for placebo group). The most commonly reported adverse effects in the LEV group were asthenia, headache, and somnolence.<\/jats:p><jats:p> <jats:italic>Conclusions<\/jats:italic>: The antiepileptic efficacy and tolerability of LEV (1,000 mg\/d and 2,000 mg\/d, administered in two divided doses) as add\u2010on therapy was established in patients with refractory partial seizures in this clinical study.<\/jats:p>","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","type":"journal-article","created":{"date-parts":[[2005,8,3]],"date-time":"2005-08-03T06:42:30Z","timestamp":1123051350000},"page":"1179-1186","source":"Crossref","is-referenced-by-count":385,"title":["Multicenter Double\u2010Blind, Randomized, Placebo\u2010Controlled Trial of Levetiracetam as Add\u2010On Therapy in Patients with Refractory Partial Seizures"],"prefix":"10.1111","volume":"41","author":[{"given":"Simon D.","family":"Shorvon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"L\u00f6wenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Janz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Bielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the European Levetiracetam Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,8,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90768-D"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00410-5"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00077-1"},{"key":"e_1_2_1_5_2","first-page":"474","article-title":"Antiepileptogenic effects of the novel anticonvulsant LEV (ucb L059) in the kindling model of temporal lobe epilepsy","volume":"284","author":"L\u00f6scher W","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00436-O"},{"key":"e_1_2_1_7_2","unstructured":"Data on file UCB Pharma Braine\u2010l'Alleud Belgium."},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00052-2"},{"issue":"2","key":"e_1_2_1_9_2","first-page":"250","article-title":"In vitro evaluation of potential drug interactions with LEV, a new antiepileptic agent","volume":"27","author":"Nicolas JM","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_10_2","unstructured":"Guidelines for good clinical practice. EC Directive 91\/507\/EEG.19 July 1991."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6977.452"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6974(96)00010-2"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.2000.tb05984.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1157.2000.tb00323.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1157.2000.tb00323.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T18:32:42Z","timestamp":1698604362000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1157.2000.tb00323.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["10.1111\/j.1528-1157.2000.tb00323.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1157.2000.tb00323.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]}}}